Published Clinical Findings On Treatment With ZOMETAŽ (zoledronic acid) In Cancer Patients

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

Recent Publications

Costa L, Major PP.
Effect of bisphosphonates on pain and quality of life in patients with bone metastases.
Nature Clinical Practice Oncology (2009)

Bundred N., et al.
Effective Inhibition of Aromatase Inhibitor-associated Bone Loss by zoledronic acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole ZO-FAST Study Results
Cancer (2008)

Hirsh V., et al.
zoledronic acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity
Journal of Thoracic Oncology (2008)

Lyseng-Williamson KA
zoledronic acid: a review of its use in breast cancer.
Drugs (2008)

R. Coleman, et. al.
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
Cancer Treatment Reviews (2008)

Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A.
zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a National Medical claims database.
Cancer (2008)

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.